Skip to main content
. 2018 Oct 18;3(20):e122591. doi: 10.1172/jci.insight.122591

Figure 7. High expression of the integrin β8 subunit and PD-L1 are rarely seen concurrently in non–small cell lung carcinoma (NSCLC).

Figure 7

(A and B) Seventy-three archival lung adenocarcinoma cases were stained for the β8 integrin subunit and PD-L1 with antibody clone F9 for β8 and antibody clone E1N3 for PD-L1. Expression was determined by tumor proportion score (TPS) for both β8 and PD-L1 and plotted on an (A) xy graph divided into TPS quadrants 0%–49% or ≥50% (P = 0.7194 by McNemar’s test; Pearson r = –0.0394; P = 0.7403), or shown by (B) TPS as 0% (open bars), 1%–49% (striped bars), or 50%–100% (filled bars) in column format.